OSNA - Enhancing the power of nodal staging

There has been an increase in the use of neoadjuvant systemic therapy (NAST) in breast cancer patients in recent years. The main indications include shrinking the primary tumour, thus reducing the extent of surgery, or enabling breast conserving surgery instead of mastectomy. Moreover, it allows an assessment of the tumour’s response to systemic therapy.
File type:
File size:
136 KB
Copyright © Sysmex Europe SE. All rights reserved.